Citations (58)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Allan W. Cripps, Temitope Folaranmi, Kelly D. Johnson, Luwy Musey, Michael S. Niederman & Ulrike K. Buchwald. (2021) Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a review of the literature. Expert Review of Vaccines 20:3, pages 257-267.
Read now
Read now
Nobuharu Ohshima, Yukihiro Akeda, Hideaki Nagai & Kazunori Oishi. (2020) Immunogenicity and safety after the third vaccination with the 23-valent pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease. Human Vaccines & Immunotherapeutics 16:9, pages 2285-2291.
Read now
Read now
Lili Huang, Ling Wang, Hong Li, Yuansheng Hu, Weiping Ru, Weixiao Han, Gang Shi, Qiang Ye, Zhen Han, Jielai Xia, Shengli Xia, Miao Xu & Jing Li. (2019) A phase III clinical trial to evaluate the safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine (PPV23) in healthy children, adults, and elderly. Human Vaccines & Immunotherapeutics 15:1, pages 249-255.
Read now
Read now
Kenji Kawakami, Hiroyuki Kishino, Shinichi Kanazu, Kenichi Takahashi, Tomoharu Iino, Miyuki Sawata & Luwy Musey. (2018) Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly. Human Vaccines & Immunotherapeutics 14:8, pages 1931-1938.
Read now
Read now
Richard Aspinall & Pierre Olivier Lang. (2018) Vaccination choices for older people, looking beyond age specific approaches. Expert Review of Vaccines 17:1, pages 23-30.
Read now
Read now
Karen Ciprero, Kirill A. Zykov, Nikolay I. Briko, Tulin Shekar, Tina M. Sterling, Elizaveta Bitieva, Jon E. Stek & Luwy Musey. (2016) Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects. Human Vaccines & Immunotherapeutics 12:8, pages 2142-2147.
Read now
Read now
Ho Namkoong, Makoto Ishii, Yohei Funatsu, Yoshifumi Kimizuka, Kazuma Yagi, Takahiro Asami, Takanori Asakura, Shoji Suzuki, Testuro Kamo, Hiroshi Fujiwara, Sadatomo Tasaka, Tomoko Betsuyaku & Naoki Hasegawa. (2016) Theory and strategy for Pneumococcal vaccines in the elderly. Human Vaccines & Immunotherapeutics 12:2, pages 336-343.
Read now
Read now
Masanari Shiramoto, Ryuzo Hanada, Christine Juergens, Yasuko Shoji, Mizuki Yoshida, Barry Ballan, David Cooper, William C Gruber, Daniel A Scott & Beate Schmoele-Thoma. (2015) Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults. Human Vaccines & Immunotherapeutics 11:9, pages 2198-2206.
Read now
Read now
Richard Aspinall & Pierre Olivier Lang. (2014) Vaccine responsiveness in the elderly: best practice for the clinic. Expert Review of Vaccines 13:7, pages 885-894.
Read now
Read now
David S Fedson. (2014) Pneumococcal conjugate vaccination for older adults. Human Vaccines & Immunotherapeutics 10:1, pages 47-51.
Read now
Read now
David S. Fedson & Martin J. Guppy. (2013) Pneumococcal vaccination of older adults. Human Vaccines & Immunotherapeutics 9:6, pages 1382-1384.
Read now
Read now
Angel Vila-Corcoles & Olga Ochoa-Gondar. (2012) Pneumococcal vaccination among adults with chronic respiratory diseases: a historical overview. Expert Review of Vaccines 11:2, pages 221-236.
Read now
Read now
Articles from other publishers (46)
Kay Choong See. (2023) Pneumococcal Vaccination in Adults: A Narrative Review of Considerations for Individualized Decision-Making. Vaccines 11:5, pages 908.
Crossref
Crossref
John D. Grabenstein & Daniel M. Musher. 2023. Plotkin's Vaccines. Plotkin's Vaccines
869
889.e12
.
Marco Vincenzo Lenti, Sarah Luu, Rita Carsetti, Faith Osier, Rodney Ogwang, Obiageli E. Nnodu, Ursula Wiedermann, Jo Spencer, Franco Locatelli, Gino Roberto Corazza & Antonio Di Sabatino. (2022) Asplenia and spleen hypofunction. Nature Reviews Disease Primers 8:1.
Crossref
Crossref
Lykke Larsen, Claus Bistrup, Søren Schwartz Sørensen, Lene Boesby, Charlotte Sværke Jørgensen & Isik Somuncu Johansen. (2022) Immunogenicity and safety of double dosage of pneumococcal vaccines in adult kidney transplant recipients and waiting list patients: A non-blinded, randomized clinical trial. Vaccine 40:28, pages 3884-3892.
Crossref
Crossref
Theano Lagousi, Ioanna Papadatou, Petros Strempas, Elena Chatzikalil & Vana Spoulou. (2021) Pneumococcal Immunization Strategies for High-Risk Pediatric Populations Worldwide: One Size Does Not Fit All. Vaccines 9:12, pages 1390.
Crossref
Crossref
O. A. Gruzdeva, T. N. Bilichenko, M. A. Baryshev & A. V. Zhukova. (2021) The impact of vaccination against influenza and pneumococcal infection on the incidence of acute respiratory viral infections and community-acquired pneumonia in the Central Administrative District of Moscow. Epidemiology and Vaccinal Prevention 20:2, pages 28-41.
Crossref
Crossref
E. Varon & J. Gaillat. (2020) Pneumocoque. Revue des Maladies Respiratoires Actualités 12, pages A6-A10.
Crossref
Crossref
Fabio Casciani, Maxwell T. Trudeau & Charles M. VollmerJrJr. (2020) Perioperative Immunization for Splenectomy and the Surgeon’s Responsibility. JAMA Surgery 155:11, pages 1068.
Crossref
Crossref
Shengwen Calvin Li & Mustafa H. Kabeer. (2020) Autologous Splenocyte Reinfusion Improves Antibody-Mediated Immune Response to the 23-Valent Pneumococcal Polysaccharide-Based Vaccine in Splenectomized Mice. Biomolecules 10:5, pages 704.
Crossref
Crossref
Alexis J. Pillsbury, Parveen Fathima, Helen E. Quinn, Patrick Cashman, Christopher C. Blyth, Alan Leeb & Kristine K. Macartney. (2020) Comparative Postmarket Safety Profile of Adjuvanted and High-Dose Influenza Vaccines in Individuals 65 Years or Older. JAMA Network Open 3:5, pages e204079.
Crossref
Crossref
C. Raina MacIntyre, Iman Ridda, Mallory J. Trent & Peter McIntyre. (2019) Persistence of immunity to conjugate and polysaccharide pneumococcal vaccines in frail, hospitalised older adults in long-term follow up. Vaccine 37:35, pages 5016-5024.
Crossref
Crossref
C Ferlito, R Biselli, M S Cattaruzza, R Teloni, S Mariotti, E Tomao, G Salerno, M S Peragallo, P Lulli, S Caporuscio, A Autore, G Bizzarro, V Germano, M I Biondo, A Picchianti Diamanti, S Salemi, R Nisini & R D'Amelio. (2018) Immunogenicity of meningococcal polysaccharide ACWY vaccine in primary immunized or revaccinated adults. Clinical and Experimental Immunology 194:3, pages 361-370.
Crossref
Crossref
Alexis J Pillsbury, Catherine Glover, Peter Jacoby, Helen E Quinn, Parveen Fathima, Patrick Cashman, Alan Leeb, Christopher C Blyth, Michael S Gold, Thomas Snelling & Kristine K Macartney. (2018) Active surveillance of 2017 seasonal influenza vaccine safety: an observational cohort study of individuals aged 6 months and older in Australia. BMJ Open 8:10, pages e023263.
Crossref
Crossref
John D. Grabenstein & Daniel M. Musher. 2018. Plotkin's Vaccines. Plotkin's Vaccines
816
840.e13
.
C. R. Laratta, K. Williams, D. Vethanayagam, M. Ulanova & H. Vliagoftis. (2017) A case series evaluating the serological response of adult asthma patients to the 23-valent pneumococcal polysaccharide vaccine. Allergy, Asthma & Clinical Immunology 13:1.
Crossref
Crossref
Heather L. Sings. (2017) Pneumococcal conjugate vaccine use in adults – Addressing an unmet medical need for non-bacteremic pneumococcal pneumonia. Vaccine 35:40, pages 5406-5417.
Crossref
Crossref
. (2017) 肺炎球菌ワクチン再接種のガイダンス （改訂版）. Kansenshogaku Zasshi 91:4, pages 543-552.
Crossref
Crossref
Jay A. Fishman, David N. Iklé & Robert A. Wilkinson. (2017)
Discrepant serological assays for
Pneumococcus
in renal transplant recipients - a prospective study
. Transplant International 30:7, pages 689-694.
Crossref
Crossref
Ekaterina A. Kurbatova, Nelli K. AkhmatovaAkhmatovaAkhmatova, Elina A. Akhmatova, Nadezhda B. Egorova, Natalya E. Yastrebova, Elena V. Sukhova, Dmitriy V. Yashunsky, Yury E. Tsvetkov, Marina L. Gening & Nikolay E. Nifantiev. (2017) Neoglycoconjugate of Tetrasaccharide Representing One Repeating Unit of the Streptococcus pneumoniae Type 14 Capsular Polysaccharide Induces the Production of Opsonizing IgG1 Antibodies and Possesses the Highest Protective Activity As Compared to Hexa- and Octasaccharide Conjugates. Frontiers in Immunology 8.
Crossref
Crossref
Anna Ljunghill Hedberg, Karlis Pauksens, Per Enblad, Jessika Söderberg, Björn Johansson, Helena Käyhty & Jan Sjölin. (2017) Pneumococcal polysaccharide vaccination administered early after neurotrauma or neurosurgery. Vaccine 35:6, pages 909-915.
Crossref
Crossref
Cornelius Remschmidt, Thomas Harder, Ole Wichmann, Christian Bogdan & Gerhard Falkenhorst. (2016) Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review. BMC Infectious Diseases 16:1.
Crossref
Crossref
G. Falkenhorst, C. Remschmidt, T. Harder, O. Wichmann, S. Glodny, E. Hummers-Pradier, T. Ledig & C. Bogdan. (2016) Background paper to the updated pneumococcal vaccination recommendation for older adults in Germany. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 59:12, pages 1623-1657.
Crossref
Crossref
Kenji Kawakami, Hiroyuki Kishino, Shinichi Kanazu, Nobuhito Toshimizu, Kenichi Takahashi, Tina Sterling, Meihua Wang & Luwy Musey. (2016) Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses. Vaccine 34:33, pages 3875-3881.
Crossref
Crossref
Robert W. FrenckJr.Jr., Anne Fiquet, Alejandra Gurtman, Martin van Cleeff, Matthew Davis, John Rubino, William Smith, Vani Sundaraiyer, Mohinder Sidhu, Emilio A. Emini, William C. Gruber, Daniel A. Scott & Beate Schmoele-Thoma. (2016) Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older. Vaccine 34:30, pages 3454-3462.
Crossref
Crossref
Paul V. Licciardi, Zheng Quan Toh, Elizabeth A. Clutterbuck, Anne Balloch, Rachel A. Marimla, Leena Tikkanen, Karen E. Lamb, Kathryn J. Bright, Uraia Rabuatoka, Lisi Tikoduadua, Laura K. Boelsen, Eileen M. Dunne, Catherine Satzke, Yin Bun Cheung, Andrew J. Pollard, Fiona M. Russell & Edward K. Mulholland. (2016) No long-term evidence of hyporesponsiveness after use of pneumococcal conjugate vaccine in children previously immunized with pneumococcal polysaccharide vaccine. Journal of Allergy and Clinical Immunology 137:6, pages 1772-1779.e11.
Crossref
Crossref
Ioanna Papadatou & Vana Spoulou. (2016) Pneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right?. Clinical and Vaccine Immunology 23:5, pages 388-395.
Crossref
Crossref
Aristine Cheng, Sui-Yuan Chang, Mao-Song Tsai, Yi-Ching Su, Wen-Chun Liu, Hsin-Yun Sun & Chien-Ching Hung. (2016) Long-term immune responses and comparative effectiveness of one or two doses of 7-valent pneumococcal conjugate vaccine (PCV7) in HIV-positive adults in the era of combination antiretroviral therapy. Journal of the International AIDS Society 19:1, pages 20631.
Crossref
Crossref
C Cordonnier, M Labopin, C Robin, P Ribaud, L Cabanne, C Chadelat, S Cesaro & P Ljungman. (2015) Long-term persistence of the immune response to antipneumococcal vaccines after Allo-SCT: 10-year follow-up of the EBMT-IDWP01 trial. Bone Marrow Transplantation 50:7, pages 978-983.
Crossref
Crossref
Stefaan J. Vandecasteele, Sara Ombelet, Sophie Blumental & Willy E. Peetermans. (2015) The ABC of pneumococcal infections and vaccination in patients with chronic kidney disease: Table 1.. Clinical Kidney Journal 8:3, pages 318-324.
Crossref
Crossref
Chelsea A. Caya, Constantina Boikos, Shalini Desai & Caroline Quach. (2015) Dosing regimen of the 23-valent pneumococcal vaccination: A systematic review. Vaccine 33:11, pages 1302-1312.
Crossref
Crossref
Christine Robin, Florence Beckerich & Catherine Cordonnier. (2015) Immunization in cancer patients: Where we stand. Pharmacological Research 92, pages 23-30.
Crossref
Crossref
C. Forstner & M.W. Pletz. (2014) PneumokokkenimpfungPneumococcal vaccination. Der Pneumologe 11:6, pages 506-515.
Crossref
Crossref
Mathias W. Pletz & Tobias Welte. 2014. Community-Acquired Pneumonia. Community-Acquired Pneumonia
266
284
.
Suzanne F. Bradley. (2014) Vaccinations for Older Adults: An Update. Current Geriatrics Reports 3:1, pages 66-72.
Crossref
Crossref
Jan Kolberg, Audun Aase, Lisbeth M. Naess, Ingeborg S. Aaberge & Dominique A. Caugant. (2014) Human antibody responses to pneumococcal surface protein A and capsular polysaccharides during acute and convalescent stages of invasive disease in adult patients. Pathogens and Disease 70:1, pages 40-50.
Crossref
Crossref
Nobuharu Ohshima, Hideaki Nagai, Hirotoshi Matsui, Shunsuke Akashi, Tomohiko Makino, Yukihiro Akeda & Kazunori Oishi. (2014) Sustained functional serotype-specific antibody after primary and secondary vaccinations with a pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease. Vaccine 32:10, pages 1181-1186.
Crossref
Crossref
David J. Leggat, Noor M. Khaskhely, Anita S. Iyer, Jason Mosakowski, Rebecca S. Thompson, John D. Weinandy & M.A. Julie Westerink. (2013) Pneumococcal polysaccharide vaccination induces polysaccharide-specific B cells in adult peripheral blood expressing CD19+CD20+CD3?CD70?CD27+IgM+CD43+CD5+/?. Vaccine 31:41, pages 4632-4640.
Crossref
Crossref
Angel Vila-Corcoles & Olga Ochoa-Gondar. (2013) Preventing Pneumococcal Disease in the Elderly. Drugs & Aging 30:5, pages 263-276.
Crossref
Crossref
Daniel M. Musher. (2013) How Effective is Vaccination in Preventing Pneumococcal Disease?. Infectious Disease Clinics of North America 27:1, pages 229-241.
Crossref
Crossref
Mark T. Dransfield, Sarah Harnden, Robert L. Burton, Richard K. Albert, William C. Bailey, Richard Casaburi, John Connett, J. Allen D. Cooper, Gerard J. Criner, Jeffrey L. Curtis, MeiLan K. Han, Barry Make, Nathaniel Marchetti, Fernando J. Martinez, Charlene McEvoy, Moon H. Nahm, Dennis E. Niewoehner, Janos Porszasz, John Reilly, Paul D. Scanlon, Steven M. Scharf, Frank C. Sciurba, George R. Washko, Prescott G. Woodruff & Stephen C. Lazarus. (2012) Long-term Comparative Immunogenicity of Protein Conjugate and Free Polysaccharide Pneumococcal Vaccines in Chronic Obstructive Pulmonary Disease. Clinical Infectious Diseases 55:5, pages e35-e44.
Crossref
Crossref
Robert W. FrenckJr.Jr., Alejandra Gurtman, John Rubino, William Smith, Martin van Cleeff, Deepthi Jayawardene, Peter C. Giardina, Emilio A. Emini, William C. Gruber, Daniel A. Scott & Beate Schmöle-Thoma. (2012) Randomized, Controlled Trial of a 13-Valent Pneumococcal Conjugate Vaccine Administered Concomitantly with an Influenza Vaccine in Healthy Adults. Clinical and Vaccine Immunology 19:8, pages 1296-1303.
Crossref
Crossref
J. D. Grabenstein. (2012) Effectiveness and Serotype Coverage: Key Criteria for Pneumococcal Vaccines for Adults. Clinical Infectious Diseases 55:2, pages 255-258.
Crossref
Crossref
John D. Grabenstein & Susan B. Manoff. (2012) Pneumococcal polysaccharide 23-valent vaccine: Long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults. Vaccine 30:30, pages 4435-4444.
Crossref
Crossref
J. Gaillat. (2012) Les vaccins antipneumococciques chez l’adulte : où en sommes-nous ?. Journal des Anti-infectieux 14:2, pages 96-103.
Crossref
Crossref
Elizabeth A. Clutterbuck, Rajeka Lazarus, Ly-Mee Yu, Jaclyn Bowman, Elizabeth A. L. Bateman, Linda Diggle, Brian Angus, Tim E. Peto, Peter C. Beverley, David Mant & Andrew J. Pollard. (2012) Pneumococcal Conjugate and Plain Polysaccharide Vaccines Have Divergent Effects on Antigen-Specific B Cells. The Journal of Infectious Diseases 205:9, pages 1408-1416.
Crossref
Crossref
John D. Grabenstein & Susan B. Manoff. (2011) Pneumococcal vaccines in adults: Assessing the evolving evidence. Vaccine 29:37, pages 6149-6154.
Crossref
Crossref